Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Boris Anafasyev"'
Autor:
Gérard Socié, Péter Reményi, Ardeshir Ghavamzadeh, Mohamad Mohty, Sebastian Giebel, Arnon Nagler, Patrice Chevallier, Myriam Labopin, Per Ljungman, Maija Itälä-Remes, Jacob Passweg, Montserrat Rovira, Nathalie Fegueux, Alessandro Rambaldi, Tomasz Czerw, Xavier Poiré, Boris Anafasyev, Didier Blaise, Martin Bornhäuser
Publikováno v:
European journal of cancer (Oxford, England : 1990), Vol. 106, p. 212-219 (2019)
BACKGROUND: Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ova
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ffa19ba3b5fb7b538c20371fea73472
https://hdl.handle.net/2078.1/237857
https://hdl.handle.net/2078.1/237857